Putative novel mediators of acute kidney injury in critically ill patients: handling by continuous venovenous hemofiltration and effect of anticoagulation modalities by unknown
RESEARCH ARTICLE Open Access
Putative novel mediators of acute kidney
injury in critically ill patients: handling by
continuous venovenous hemofiltration and
effect of anticoagulation modalities
Louise Schilder1*, S. Azam Nurmohamed1, Pieter M. ter Wee1, Nanne J. Paauw2, Armand RJ Girbes3,
Albertus Beishuizen4, Robert HJ Beelen2 and AB Johan Groeneveld5
Abstract
Background: Novel putative mediators of acute kidney injury (AKI) include immune-cell derived tumour necrosis
factor-like weak inducer of apoptosis (TWEAK), angiopoietin-2 (Ang-2) and protein pentraxin-3 (PTX3). The effect of
continuous venovenous hemofiltration (CVVH) and different anticoagulation regimens on plasma levels were studied.
Methods: At 0, 10, 60, 180 and 720 min of CVVH, samples were collected from pre- and postfilter blood and
ultrafiltrate. No anticoagulation (n = 13), unfractionated heparin (n = 8) or trisodium citrate (n = 21) were compared.
Results: Concentrations of TWEAK, Ang-2 and PTX3 were hardly affected by CVVH since the mediators were not
(TWEAK, PTX3) or hardly (Ang-2) detectable in ultrafiltrate, indicating negligible clearance by the filter in spite of
molecular sizes (TWEAK, PTX3) at or below the cutoff of the membrane. Heparin use, however, was associated with
an increase in in- and outlet plasma TWEAK.
Conclusion: Novel AKI mediators are not cleared nor produced by CVVH. However, heparin anticoagulation increased
TWEAK levels in patient’s plasma whereas citrate did not, favouring the latter as anticoagulant in CVVH for AKI.
Keywords: Acute kidney injury, Citrate, Continuous venovenous hemofiltration, Critically ill patients, TWEAK,
Angiopioetin-2, Pentraxin-3
Background
Acute kidney injury (AKI) is common in critically ill pa-
tients, particularly in case of sepsis, and is associated with
increased morbidity and mortality even in the long term
[1]. Although the pathogenesis of AKI is multifactorial,
novel mediators have been described that are implicated in
the development of AKI, for instance in the course of sep-
sis. These mediators include TNF-associated weak inducer
of apoptosis (TWEAK), a member of the super tumor ne-
crosis factor (TNF) family, which can be expressed in renal
and immune cells [2, 3]. Also, angiopoietin-2 (Ang-2), a
proinflammatory and endothelial barrier-destabilizing
mediator in the vessel wall and macrophages, has
been described to play a role in AKI and has been re-
ported to be a predictor of mortality in patients with
dialysis-dependent AKI [4–6]. Finally, pentraxin-3 (PTX3)
is an acute phase protein located in endothelium and
stored in neutrophils, that recently is considered to play a
role in the pathogenesis of ischemic acute kidney injury,
although renal protective effects have been described as
well [7, 8].
Continuous venovenous hemofiltration (CVVH) is
often applied in the treatment of AKI and clearance and
absorption by the filter membrane of harmful sub-
stances, dependent on molecular weight and membrane
properties among others, remain a controversial issue. It
has been postulated that citrate, used for filter anticoa-
gulation, prevents, partly by chelating calcium, degranu-
lation of neutrophils induced by systemic heparin
following complement activation and blood filter contact
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during CVVH [9, 10]. Hence, the anticoagulation regi-
men applied during CVVH could influence release of
proinflammatory factors and specific AKI mediators by
activated immune cells and platelets in the patient and
hemofilter.
The aim of the current study was to assess how the
novel, putative mediators of AKI are handled by CVVH
and whether different anticoagulation regimens have
additional effects, in critically ill patients with AKI.
Methods
The patient population and methods for this study are
reported elsewhere [10, 11]. Study protocols were ap-
proved by the local medical ethical committee and per-
formed in accordance with the Declaration of Helsinki.
Patients were recruited during office hours for sampling
when participating in one of the two following studies.
The first study started 1 year before the availability of a
custom-made citrate-based replacement fluid. From
March 2004 to September 2005, patients admitted to the
intensive care unit (ICU) who developed AKI necessitat-
ing CVVH but in whom heparin was contraindicated
due to a high bleeding tendency, were either treated by
anticoagulant-free CVVH (n = 13) or, after becoming
available in 2005, by regional citrate anticoagulation
(n = 10) and were prospectively followed [12]. High risk
for bleeding was arbitrarily defined as a platelet count of
less than 40 × 109/L, an activated partial thromboplastin
time (aPTT) of more than 60 s, a prothrombin time of
more than 2.0 international normalized ratio, a recent
major bleeding, or active bleeding. Because all patients
were treated according to local standards, the need for in-
formed consent was waived for this study. Patients were
also recruited from a second study, which is a randomized
controlled trial initiated in 2006 (the so called ‘Citrate
anticoagulation versus systemic heparinization’, CASH
trial, clinicaltrials.gov number NCT00209378) [13]. Pa-
tients admitted to the ICU of the VU University Medical
Center who developed AKI necessitating CVVH without a
high bleeding risk, were randomised between unfractio-
nated heparin as anticoagulant (n = 8) or citrate (n = 11).
Informed consent was obtained from all study participants
or their next-of-kin. We pooled the studies because of the
mechanistic nature of the current paper, without focus on
patient-centered outcomes.
Treatment protocol
The indication for CVVH was based on standard clinical
criteria that include AKI accompanied by hemodynamic
instability, ongoing hypercatabolism, diuretic-resistant
fluid overload, respiratory distress, multiorgan failure, or
some combinations of these factors. CVVH was per-
formed using a hemofiltration machine (DIAPACT, B.
Braun Medical, Melsungen, Germany). Vascular access
was obtained by the insertion of an 11 F double-lumen
catheter (GamCathtm, Gambro, Hechingen, Germany) into
the femoral, subclavian, or jugular vein. A 1.9 m2 highly
permeable cellulose triacetate filter (NIPRO UF-205,
Nissho Corp, Osaka, Japan, cut-off approximately 40 kDa)
was used in all treatments. For lactate- or bicarbonate-
based CVVH, commercially prepared buffer solutions
were used (BH504 or HF32bic respectively, Dirinco,
Rosmalen, the Netherlands). Patients with high serum
lactate levels (>5 mmol/L) were routinely treated with
bicarbonate-buffered rather than lactate buffered CVVH.
For the use of citrate, a replacement solution was custom-
made by Dirinco (Rosmalen, the Netherlands). Blood flow
rate was set at 180 mL/min in all groups. Replacement
fluid was administered at a standard rate of 2000 mL/h in
the patients receiving no anticoagulation or heparin with
bicarbonate or lactate-containing replacement fluids. Re-
placement fluid rate in the citrate group was set at
2400 mL/h and in all cases replacement fluids were
infused in predilutional mode. Patients on heparin were
administered prefilter a heparin bolus of 5000 IU followed
by a body weight based continuous infusion targeting an
aPTT between 45 and 55 s. Patients receiving citrate-
based therapy had a separate intravenous infusion
with calcium glubionate (Calcium Sandoz, containing
0.225 mmol/mL calcium, Novartis Consumer Health,
Breda, The Netherlands). Calcium administration was
adapted to concentrations of ionized calcium in the pa-
tient by a specially designed algorithm, as described before
[12]. The target ionized calcium concentration in the cir-
cuit was 0.3 mmol/L, but not routinely monitored since
this is almost uniformly achieved with the aforementioned
settings [12]. Filters were used for 72 h at maximum and
electively replaced if needed (n = 1 functioned well beyond
t = 72 h).
Study protocol
At inclusion, demographic variables were recorded such as
age, gender and reason of ICU admission. Assessment of
disease severity on ICU admission was done according to
the Acute Physiology And Chronic Health Evaluation II
(APACHE II), the Simplified Acute Physiology Score II
(SAPS II) and the Sequential Organ Failure Assessment
score (SOFA). We collected systemic inflammatory re-
sponse syndrome (SIRS) criteria: body temperature >38 °C;
a heart rate of >90 beats/min; a respiratory rate of >20
breaths/min or mechanical ventilation; and white blood
cell counts of <4.0 *109/L or >12.0 *109/L. When SIRS
(two or more criteria) and an infection were present (either
clinically suspected or microbiologically confirmed), pa-
tients were classified as having sepsis. Venous blood sam-
ples were collected from the hemofiltration catheter from
each patient before the initiation of CVVH and adminis-
tration of heparin. Heparin was given immediately after
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filter connection. Thereafter, blood samples were collected
after 10, 60, 180 and 720 min from the pre- and post filter
pole (at t = 180 93 % and at t = 720 min 68 % of filters were
patent and allowed sampling). In 40/42 (96 %) patients the
first filter run was studied; in two patients a later filter run
was studied because of technical reasons.
Prefilter blood was invariably drawn before addition of
replacement fluids and thus reported concentrations of
the markers at inlet are not diluted. Leukocytes, platelets
and serum creatinine concentrations were measured be-
fore initiation of CVVH and routinely thereafter. In all
patients, a zero fluid balance was achieved during the
time points at which blood samples were drawn. Ultrafil-
trate samples were collected from the appropriate ports.
Samples were collected in standard Vacutainer tubes
(Becton, Dickinson and Company, Erembodegem,
Belgium) with ethylenediaminetetraacetic acid (EDTA),
benzamidine and soybean trypsin inhibitor added. Sam-
ples were centrifuged at 1,300 g for 10 min at 4 °C and
stored at−80 °C until assayed.
Measurements and calculations
Concentrations of TWEAK (molecular weight (Mw) 30–
35 kDa, in healthy adults 34–500 pg/mL [14]), Ang-2 (Mw
57–70 kDa, in healthy adults 0.3–2.6 ng/mL [15]), and
PTX-3 (Mw 40–45 kDa, in healthy adults <2 ng/mL [16])
were measured by enzyme-linked immunosorbent assays
(ELISAs). Plasma samples and ultrafiltrate were measured
in separate assays with standards prepared in a 0.5 % bovine
albumin serum phosphate buffered saline tween solution
or fresh ultrafiltrate as appropriate. Commercially available
antibody duosets were used (for TWEAK: Human
TWEAK/TNFSF12, R&D Systems, UK, DY1090, for Ang-
2: Human Ang-2, R&D Systems, UK, DY623, for PTX-3:
Human pentraxin 3-TSG-14, R&D Systems, UK, DY1826).
All measurements were done according to the protocols
provided by the manufacturer. Each sample was run in
duplicate and the mean concentration was calculated.
Formulas used to evaluate fluxes are described in Table 1.
Statistical analysis
Due to mostly non-Gaussian distributions, data are pre-
sented as median and range. Since there were no base-
line differences between the two citrate groups (citrate
vs. no-anticoagulation and citrate vs. heparin), the citrate
data were pooled. When appropriate, data were log-
transformed to achieve normal distributions. The values
for the total mass removal rate were ranked, since some
values were negative and could not be log-transformed.
Group differences were evaluated using X2 or Kruskal-
Wallis tests, where appropriate. To evaluate differences
according to anticoagulation regimens in time we used
generalized estimating equations (GEE) taking repeated
measurements in the same patient into account. The focus
of GEE is on estimating differences between anticoagula-
tion groups and time points, and their first order inter-
action, i.e. differences between anticoagulation groups
over time, and associated P values are reported. Spearman
correlation coefficients were used to express relations.
A P <0.05 was considered statistically significant. Exact P
values are given unless <0.001.
Results
Patient characteristics
At baseline, all patients included in this study (n = 42) met
the criteria for SIRS and 18 of 42 (43 %) patients met the
criteria for sepsis. The no anticoagulation group had higher
disease severity scores than the other groups (Table 2).
TWEAK
Concentrations at in- and outlet were higher in the
heparin group than other groups (P = 0.043 and P = 0.001,
respectively), especially after 10 min of CVVH, and con-
centrations at in- and outlet decreased over time in the
heparin group but not in the other groups (P = 0.001 and
P = 0.007, respectively). TWEAK was not detectable in the
ultrafiltrate and the total mass removal rate and thus ab-
sorption were low and did not differ between anticoagula-
tion groups (Fig. 1).
Ang-2
Concentrations at inlet minimally decreased over time in
all groups (P = 0.001) and concentrations at outlet were
similar to those at inlet, yet did not change over time in
any of the groups. Ang-2 was detectable in 43 % of the
total measurements in the ultrafiltrate; concentrations were
low, approximately 4 % of inlet levels, and concentrations
somewhat decreased over time in the no anticoagulation
Table 1 Formulas used to evaluate fluxes
Qi = Qb x (1-Ht), Qo = Qi
Mi = Qi x Ci
Mo = Qo x Co
Muf = Quf x Cuf
Mtr = Mi - Mo
C = Ci x Qi/(Qi + RF)
SC = 2 × Cuf/(C + Co)
Ci Concentration in inlet plasma before addition of replacement fluid (ng/mL)
Co Concentration in outlet plasma (ng/mL)
Cuf Concentration in ultrafiltrate (ng/mL)
C Concentration in inlet plasma after addition of replacement fluid (ng/mL)
Qb Inlet blood flow rate (mL/min)
Qi Inlet plasma flow rate (mL/min)
Qo Outlet plasma flow rate (mL/min)
Quf Ultrafiltration flow rate (mL/min)
Mi Mass inlet rate (ng/min)
Mo Mass outlet rate (ng/min)
Muf Mass ultrafiltration rate (ng/min)
Mtr Total mass removal rate (ng/min)
RF Replacement fluid flow rate (mL/min)
SC Sieving coefficient
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group, but not the other groups (P < 0.001). The sieving co-
efficient was low with medians ranging from 0.01 to 0.1
and decreased over time in the no anticoagulation group,
but not the other groups (P < 0.001). Also, the total mass
removal rate was zero, since concentrations of Ang-2 in
the ultrafiltrate were negligible compared to in- and outlet
concentrations, and did not differ between groups over
time. Hence, there was no absorption either (Fig. 2).
PTX3
Concentrations at inlet minimally decreased over time in
the no anticoagulation and citrate group, but not in the
heparin group (P = 0.009 for interaction anticoagulation
and time). Concentrations at outlet were similar and did
not change over time in any of the anticoagulation groups.
PTX3 was not detectable in the ultrafiltrate and the total
mass removal rate (and thus absorption) was low and did
not differ between anticoagulation groups (Fig. 3).
Correlations
There was no correlation between TWEAK, Ang-2 or
PTX3 and creatinine levels at initiation of CVVH.
Plasma levels of TWEAK, Ang-2 and PTX3 at inlet at
the start of CVVH correlated with those at the end of
Table 2 Patient characteristics
No anticoagulation Heparin Citrate
n = 13 n = 8 n = 21 P
Age, yrs 70 (34–84) 57 (23–81) 64 (32–84) 0.49
Sex, male 7 (54) 6 (75) 14 (75) 0.59
Weight, kg 70 (50–100) 74 (55–135) 78 (60–110) 0.41
Sepsis 5 (39) 5 (63) 8 (38) 0.46
APACHE II at ICU admission 28 (11–42) 22 (15–37) 25 (14–41) 0.47
SAPS II at ICU admission 75 (43–112) 47 (37–77) 52 (32–86) 0.002
Creatinine, μmol/L 249 (100–410) 420 (156–626) 326 (47–622) 0.01
Urea, mmol/L 21 (6–48) 32 (12–97) 21 (6–41) 0.25
Leukocytes, ×109/L 8 (1–17) 12 (7–20) 12 (1–26) 0.29
Platelets, ×109/L 65 (22–173) 167 (44–352) 118 (35–332) 0.03
Prescribed CVVH dose, mL/kg/h 22 (16–32) 22 (11–32) 23 (16–31) 0.68
Median (and range) or number (percentage). APACHE II Acute Physiology and Chronic Health Evaluation II, ICU intensive care unit, SAPS II Simplified Acute
Physiology Score II
Fig. 1 Concentration (median and interquartile range) of TWEAK during CVVH over time at inlet (before addition of replacement fluid) and outlet
and the total mass removal rate. Symbols: ● no anticoagulation, ■ heparin,▲ citrate. Concentrations at inlet and outlet were higher in the
heparin group (P = 0.043 and P = 0.001, respectively) and decreased over time as compared to the other groups (P = 0.001 and P = 0.007, respectively)
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Fig. 2 Concentration of angiopoietin-2 during CVVH over time at inlet (before addition of replacement fluid), outlet, ultrafiltrate, and total mass
removal rate and sieving coefficient (median and interquartile range). Symbols: ● no anticoagulation, ■ heparin,▲ citrate. The concentration at
inlet minimally decreased over time, irrespective of anticoagulation (P = 0.001). The concentration in ultrafiltrate decreased over time in the no
anticoagulation group, but not in the other groups (P < 0.001). The sieving coefficient decreased in the no anticoagulation group, but not in the
others groups (P < 0.001 for interaction anticoagulation and time)
Fig. 3 Concentration (median and interquartile range) of pentraxin-3 (PTX-3) during CVVH over time at inlet (before addition of replacement
fluid), outlet and the total mass removal rate. Symbols: ● no anticoagulation, ■ heparin,▲ citrate. Concentrations at inlet decreased over time in
the no anticoagulation and citrate group, but not in the heparin group (P = 0.009 for interaction anticoagulation and time)
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the CVVH run (rs = 0.68, rs = 0.85, rs = 0.73, respect-
ively, all P < 0.001), suggesting good reproducibility of
measurements.
Sepsis and mortality
Concentrations of TWEAK were higher in patients with
sepsis (606 (236–28549) pg/mL) than in patients without
sepsis (493 (121–2181, P = 0.011). 16 of the 42 (38 %)
patients died in the ICU. Plasma levels of Ang-2 and
PTX3 at inlet were higher in non-survivors at initiation
of CVVH: 16 (1.2–230) vs 9.6 (0.6–34) ng/mL, P = 0.019
and 34 (7.4–235) vs 27 (6.9–187) ng/mL, P = 0.015,
respectively.
Discussion
The present study shows that plasma levels of putative
novel AKI mediators in critically ill patients are not af-
fected by CVVH; there is no clearance, absorption nor
production across the system. Although inlet (patients
plasma) concentrations of Ang-2 and PTX3 are slightly
declining in the study interval, there is no or hardly any
net removal by CVVH. However, heparin anticoagulation
increases TWEAK levels in the patient whereas citrate
does not, favouring the latter as anticoagulation during
CVVH. Indeed, the result may help to explain less rapid
AKI recovery when nadroparin is used for anticoagulation
during CVVH, as compared to citrate [17].
The reason that heparin is associated with transiently
increased TWEAK in the patients, especially early after
administration, is conjectural but may relate to proin-
flammatory actions of high concentrations of heparin
[18]. Platelet activation by heparin may also play a role
since TWEAK is also stored in platelets [19]. High con-
centrations of TWEAK are undesirable, especially in an
inflammatory microenvironment, and neutralizing anti-
TWEAK antibodies, as a tissue protection strategy in
kidney disease, are currently being explored [20]. Even
though the concentration of TWEAK decreased over
time in the heparin group, there was no net removal of
TWEAK by CVVH, since in- and outlet concentration
were similar. Also, this suggests the increase of TWEAK
by heparin early in CVVH occurs in the patients rather
than in the filter or extracorporeal circuit.
We cannot explain, except by effects of spherical
configuration and electrical load of the molecules why
Ang-2, a relatively large molecule, was found in the ul-
trafiltrate, albeit at low concentrations, and TWEAK and
PTX3 with molecular weight at or below the membrane
cutoff were not. Although the concentration of Ang-2
decreased slightly at inlet but not outlet, there was no
evidence of production of Ang-2 in the filter. Also, there
was no significant production of PTX3 in the filter, thus
concentrations at inlet did not increase during the
CVVH run, in contrast to a previous study in which
PTX3 increased after a single session of hemodialysis
[21]. Therefore, concentrations of Ang-2 and PTX3 were
not affected by CVVH, irrespectively of the anticoagula-
tion method.
The mediators studied bare some relation with sepsis
and mortality, supporting their biological importance in
the critically ill. However, we could not establish a rela-
tion with creatinine to suggest a mediator role of circu-
lating factors in the development of AKI in our patients,
but confounding factors may be involved, such as time
factors, patient selection, muscle mass and others. In
any case the levels of these mediators were supranormal
in our patients cohort.
The limitations of the present study include the rela-
tively small size of groups and the absence in part of ran-
domisation, explaining some baseline differences among
the groups. Patients in the no anticoagulation group did
not receive anticoagulation because of a bleeding tendency
and, indeed, were more severely ill at baseline and lower
platelet counts. We cannot exclude earlier start of CVVH
in the no anticoagulation group than in the other groups,
since initial creatinine was lower, but this does not invali-
date our conclusions of our pathophysiologic study. Fur-
thermore, we have evaluated the course of the study
variables for a period up to 12 h only, and do not exclude
changes beyond that time interval.
Conclusions
In conclusion, plasma levels of three putative novel AKI
mediators (TWEAK, Ang-2, PTX3) in critically ill pa-
tients are not affected by CVVH, since clearance and ab-
sorption by the filter were low. Nevertheless, heparin
treatment was associated with a rise in TWEAK concen-
trations whereas citrate was not, suggesting that citrate
is more suitable for anticoagulation in CVVH for AKI.
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